Zurich, Switzerland (ots) - A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO ...
Lugano (ots) - Helsinn, the chemical pharmaceutical group based in Lugano and Biasca is pleased to announce today that it has awarded a grant for the sum of CHF 30'000 to the Institute of Research in Biomedicine (IRB) in Bellinzona, under the direction of Prof. Dr. Antonio Lanzavecchia. The grant will be used for research work performed by Prof. Markus Manz, in the ...
Lugano (ots) - Today the Swiss pharmaceutical group Helsinn announced the acquisition, of the US biopharmaceutical company, Sapphire Therapeutics Inc. with headquarters in Bridgewater, New Jersey, for an undisclosed amount. The establishment of a US-based R&D and commercial operation represents attainment of ...
Lugano, Switzerland (ots) - Helsinn is delighted to announce that its drug product manufacturing facility in Dublin, Ireland, Helsinn Birex Pharmaceuticals, has recently obtained an authorisation for Manufacture of Investigational Medicinal Products (IMP) for products for human use from the Irish Medicines Board ...
Lugano, Switzerland (ots) - Helsinn Healthcare's Top management today announced that it has signed a partnering agreement with Zealand Pharma, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a debilitating condition affecting ...
New data on the mechanism of action of the second generation 5-HT3 antagonist palonosetron presented today at the 33rd ESMO Congress in Stockholm, Sweden Stockholm, Sweden (ots) - New data presented today at the 33rd ESMO (European Society of Medical Oncology) Congress in Stockholm may contribute to explain the reason why palonosetron, a second generation 5-HT3 ...
Dublin, Ireland (ots) - Helsinn is pleased to announce that Helsinn Birex Pharmaceuticals, its drug facility in Dublin Ireland, has undergone a successful inspection by the US Food and Drug Administration (FDA) without any Form 483 observations. The FDA visit, which lasted 5 days, was a pre-approval inspection ...
Lugano (ots) - Helsinn's Top Management and its U.S. partner Eisai Inc. today announced the availability in the USA of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI® for PONV ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner EISAI Corporation of North America and EISAI's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi® (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for ...
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, today announced that it has signed a Distribution and License Agreement for Aloxi® (Palonosetron hydrochloride) and Gelclair® in Germany with Riemser Arzneimittel AG, a medium-sized pharmaceutical group engaging in research, headquartered in ...
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
LUGANO, Switzerland and MINNEAPOLIS, MN (ots) - Helsinn Healthcare S.A., Switzerland, a privately owned pharmaceutical group and its partner, MGI Pharma (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Capsules for oral ...
Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...
London (ots) - Helsinn's Top Management today announced the positive outcome of the EMEA procedure, according to Article 107, initiated due to concerns over serious liver problems. The Committee for Medicinal Products for Human Use (CHMP) today confirmed Nimesulide's positive benefit/risk profile. The benefits of these medicines outweigh their risks, but there ...
PDUFA date of 4th March 4, 2008 established Lugano (ots) - Helsinn's Top Management today announced that the supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting was accepted for filing by the United States Food and Drug Administration (FDA). Aloxi is approved by the FDA ...
Lugano (ots) - With reference to the Irish Medicine Board (IMB) decision, mainly based on 6 cases of hepatic damage, to suspend the marketing and sale of nimesulide and following the request to the European Committee for Medicinal Products for Human Use (CHMP) to revise the benefit/risk profile of the drug, Helsinn Healthcare deems opportune to specify that nimesulide is a drug with a positive safety profile as ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV) has been submitted to the U.S. Food and Drug ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary ...
Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...
Lugano/Johannesburg (ots) - HELSINN HEALTHCARE SA, and PFIZER LABORATORIES (PTY) LTD, announce the signing of an agreement granting PFIZER in South Africa, the exclusive license and distribution rights of Aloxi® (Palonosetron hydrochloride), a therapy for the prevention of nausea and vomiting induced by ...
Lugano, Switzerland and Stockholm, Sweden (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and BIOVITRUM AB, a Swedish Biotechnology company, announce the signing of an agreement granting BIOVITRUM the exclusive License and Distribution rights of Aloxi® (Palonosetron hydrochloride) in the NORDIC ...
Lugano (ots) - HELSINN HEALTHCARE SA signed an Agreement with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi® (palonosetron hydrochloride) in France, Belgium, Luxemburg and The Netherlands. Aloxi® is a strong and long-lasting antiemetic belonging to ...
Lugano, Switzerland and Lisboa, Portugal (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the signing of an agreement granting ANGELINI the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in PORTUGAL. ALOXI® is a strong and long acting ...
South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
Biasca, Switzerland (ots) - Helsinn Chemicals SA and Helsinn Advanced Synthesis SA have successfully passed a re-certification audit of its ISO14001 Environmental Management System. The audit by SGS took place on May 2nd and 3rd 2005. In parallel, Helsinn has also applied for an audit from SGS to inspect the Helsinn sites in relation to the Occupational Health and Safety Assessment Series (OHSAS) 18001 ...
Lugano, Switzerland, and Ljulubiana (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and PHARMASWISS, a Pharmaceutical company based in SLOVENIA, announce the signing of an agreement granting PHARMASWISS the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in ...
Lugano Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, announced today that the European Commission has granted the marketing authorisation for their new drug ALOXI®. This announcement comes approximately three months after the CHMP's recommendation to approve ALOXI" for the prevention of acute nausea and vomiting associated with highly ...
LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a Pharmaceutical company based in AUSTRIA, announce the signing of an agreement granting CSC the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in Austria and other countries in Central and Eastern Europe. ALOXI® is ...